Dr. Donna Supko joined ONO PHARMA USA, INC. in June 2020 as the Vice President of Regulatory Affairs where she is responsible for regulatory activities supporting the development and commercialization of the U.S. product portfolio.  

Donna has over 30 years of experience in drug development and regulatory affairs encompassing drug, biologic, device, and combination products across multiple therapeutic areas. Her regulatory experience spans several small biotech companies as well as larger companies, including EMD Serono, where she had global responsibility for the development portfolio, Sanofi-Genzyme, where she led global Oncology Regulatory Affairs, Eisai Pharmaceuticals, and Stryker Biotech. Throughout her career, Donna has been responsible for 11 successful marketing authorization applications, including 5 in the oncology therapeutic area. 

Donna earned her Ph.D. in Pharmacology from Ohio State University College of Pharmacy and completed her postdoctoral fellowship at Johns Hopkins University School of Medicine, Department of Neurology, Kennedy Krieger Institute. She also holds a M.S. in Pharmaceutics and Pharmaceutical Chemistry from Ohio State University and a B.S. in Pharmacy from Philadelphia College of Pharmacy.